-
-
SBIR-STTR Success: Charlesson LLC/EYECRO
Macular Degeneration is the leading cause of blindness and vision loss in people over 50 –and with life expectancies well into the 80s, it is estimated that 1 and 3 elderly individuals will have to deal with this degenerative disease. The remedy? Monthly injections (via needle) into the back of the eye, where the disease…
-
Bio Matters: Family influences led eyecro’s executive into scientific research
Rafal Farjo, Ph.D. is chief operating officer of both eyecro and Charlesson, which are involved in research to advance treatments for eye disease such as age-related macular degeneration, diabetic retinopathy and ocular inflammation. Far from resisting his family’s interest in all things STEM — science, technology, engineering and math — Farjo embraced it. “I loved it, and…
-
eyecro co-authors paper in Molecular and Cellular Biology studying mechanisms leading to Diabetic Retinopathy
Serum retinol-binding protein (RBP4) is the sole specific transport protein for retinol in the blood, but it is also an adipokine with retinol-independent, pro-inflammatory activity associated with obesity, insulin resistance, type 2 diabetes, and cardiovascular disease. Here we show that RBP4-Tg mice develop progressive retinal degeneration, characterized by photoreceptor ribbon synapse deficiency and subsequent bipolar…
-
Amarantus Announces the Presentation of Data Showing MANF”s Positive Effect on Retinal Function at Association for Research in Vision and Ophthalmology (ARVO) Annual Meeting
Amarantus BioScience Holdings, Inc. announced the presentation of positive preclinical data for MANF (mesencephalic-astrocyte-derived neurotrophic factor) in retinitis pigmentosa (RP) at the Association for Research in Vision and Ophthalmology Annual Meeting, being held in Denver, CO. The results from preclinical studies demonstrate that MANF preserves the light-sensing function of photoreceptor cells in a genetic model of…
